<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041765</url>
  </required_header>
  <id_info>
    <org_study_id>19-11-432</org_study_id>
    <nct_id>NCT04041765</nct_id>
  </id_info>
  <brief_title>IgM-Enriched Immunoglobulin for Neonatal Sepsis</brief_title>
  <official_title>Efficacy of Prophylactic IgM-Enriched Immunoglobulin for the Management of Early-Onset Neonatal Sepsis in Very Low Birth Weight Preterm Neonates; A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares giving prophylactic IgM enriched Intravenous Immunoglobulin (IVIG) with
      placebo in 1 hour after birth, in neonates with risk factors of Early-Onset Neonatal Sepsis
      (EONS). In addition to the intervention, standard regimen antibiotics are also given within 1
      hour. The IVIG is given for 3 days and primary and secondary outcomes will be collected. Risk
      factors are both from maternal and neonate origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized-controlled trial conducted in Cipto Mangunkusumo Hospital, Jakarta, Indonesia
      aims to determine the efficacy of prophylactic IgM-Enriched IVIG in preventing EONS. A total
      of 70 very low birth weight (VLBW) neonates with risk factors for EONS including maternal
      factors of premature rupture of membrane (PROM), fever, urinary tract infection (UTI),
      chorioamnionitis, and neonatal factor of prematurity and resuscitation history will be
      collected. These neonates within 1 hour of life will then be administered either placebo or
      IgM-enriched IVIG 0.25g/kg/day for 3 days, in addition to first-line empiric antibiotic.
      Randomization is done using simple randomization. Triple masking (Participant, Investigator,
      Outcomes Assessor) is conducted.

      These neonates will then be clinically observed and evaluated for early mortality (mortality
      below 7 days), hemodynamics, length of stay, blood culture results, C-Reactive Protein (CRP),
      IT ratio, routine hematological examination, and IgGAME as parameters of improvement and
      prevention of EONS.

      STATA version 12 (Macintosh version) will be used for data management and statistical
      analyses. The variables will first be presented descriptively, continued with bivariate and
      multivariate analysis. Bivariate analysis will be conducted between independent and dependent
      variables using chi-square/Fisher's exact test, Student's t-test, and Kruskal-Wallis.
      Variables with p-values &lt;0.25 will be included in the multivariate analysis using logistic
      regression. The investigators will use two-sided p-values in our analysis with a p &lt; 0.05
      level of significance.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Mortality Rate</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have lower mortality rate in the first week of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive blood culture</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have less number of positive blood culture than those in the place group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of NICU stay</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Neonates in the treatment group should be discharged earlier than those in the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative CRP Levels</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have lower CRP levels than those in the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IT Ratio value</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have lower IT Ratio value than those in the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte count</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have lower Leukocyte count than those in the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgGAME (IgG, IgM, IgA, IgE) Levels</measure>
    <time_frame>1 week</time_frame>
    <description>Neonates in the treatment group should have higher IgGAME levels than those in the placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Neonatal Sepsis, Early-Onset</condition>
  <condition>Very Low Birth Weight Infant</condition>
  <condition>Inflammation</condition>
  <condition>Infant, Newborn, Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Antibiotics only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IgM-enriched IVIG</intervention_name>
    <description>Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Pentaglobin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Very low birth weight infants (&lt; 1500 g)

          -  Gestational age below 32 weeks

          -  Risk of Early-Onset sepsis from maternal and neonate factors

          -  Inborn neonates

        Exclusion Criteria:

          -  Birth weight &lt; 600 g

          -  Gestational age &lt; 26 weeks

          -  Multiple Congenital Anomaly

          -  Neonates with suspected congenital syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Hour</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rinawati Rohsiswatmo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nina D Putri, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rinawati Rohsiswatmo, MD, PhD</last_name>
    <phone>+62811133094</phone>
    <email>rinarohsis@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Capasso L, Borrelli AC, Parrella C, Lama S, Ferrara T, Coppola C, Catania MR, Iula VD, Raimondi F. Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants? Ital J Pediatr. 2013 Oct 7;39:63. doi: 10.1186/1824-7288-39-63.</citation>
    <PMID>24098953</PMID>
  </reference>
  <reference>
    <citation>Haque KN, Zaidi MH, Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988 Dec;142(12):1293-6.</citation>
    <PMID>3195529</PMID>
  </reference>
  <reference>
    <citation>Reith HB, Rauchschwalbe SK, Mittelkötter U, Engemann R, Thiede A, Arnold A, Lissner R. IgM-enriched immunoglobulin (pentaglobin) positively influences the course of post-surgical intra-abdominal infections. Eur J Med Res. 2004 Oct 29;9(10):479-84.</citation>
    <PMID>15546815</PMID>
  </reference>
  <reference>
    <citation>Capasso L, Borrelli AC, Pirozzi MR, Bucci L, Albachiara R, Ferrara T, Raimondi F. IgM and IgA enriched polyclonal immunoglobulins reduce short term mortality in extremely low birth weight infants (ELBW) with sepsis: a retrospective cohort study. Minerva Pediatr. 2018 Feb 19. doi: 10.23736/S0026-4946.18.04850-8. [Epub ahead of print]</citation>
    <PMID>29460549</PMID>
  </reference>
  <reference>
    <citation>Capasso L, Borrelli AC, Ferrara T, Coppola C, Cerullo J, Izzo F, Caiazza R, Lama S, Raimondi F. Immunoglobulins in neonatal sepsis: has the final word been said? Early Hum Dev. 2014 Sep;90 Suppl 2:S47-9. doi: 10.1016/S0378-3782(14)50013-8. Review.</citation>
    <PMID>25220128</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Rinawati</investigator_full_name>
    <investigator_title>Principal Investigator; Senior Clinical Staff of Perinatology Division, Department of Child Health, Cipto Mangunkusumo Hospital; Head of Kiara Center of Maternal and Child Health, Cipto Mangunkusumo Hospital</investigator_title>
  </responsible_party>
  <keyword>IgM-enriched Intravenous Immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

